CA6 Overexpression serves as an inclusion eligibility criterion in 2 clinical trials, of which 0 are open and 2 are closed. Of the trials that contain CA6 Overexpression as an inclusion criterion, 1 is phase 1 (0 open) and 1 is phase 2 (0 open).
Trials with CA6 Overexpression in the inclusion eligibility criteria most commonly target breast carcinoma and malignant solid tumor .
Anti-ca6-dm4 immunoconjugate sar566658 is the most frequent therapy in trials with CA6 Overexpression as an inclusion criteria .
Significance of CA6 Overexpression in Diseases
Breast Carcinoma +
CA6 Overexpression is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CA6 Overexpression and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) .
Anti-ca6-dm4 immunoconjugate sar566658 is the most frequent therapy in trials for breast carcinoma that contain CA6 Overexpression .
Malignant Solid Tumor +
CA6 Overexpression is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains CA6 Overexpression and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.